Report projects global orphan drug market to tap $112 billion in 2017
By Mia Burns
The total market value for orphan drugs is expected to hit $112 billion in 2017 after increasing at a five-year compound annual growth rate of 5.4 percent, according to a new report from BCC Research, which is a publisher of technology market research reports based in Wellesley, Mass. In 2011, the global market for orphan drugs was valued at $82.6 billion in 2011 and nearly $86 billion in 2012.
Orphan drugs treat orphan diseases, which are the diseases that do not receive significant investment, research, or attention from the medical and pharmaceutical industries. These diseases tend to be rare and are defined by using a ratio of incidence to population in the United States, the European Union, Japan, and other developed countries. In addition, an orphan disease can be a tropical disease whose typical sufferers cannot afford access to pharmaceutical treatment options.
Prior to the passing of the first Orphan Drug Act in 1983 in the United States, orphan diseases did not garner much attention from the pharma industry. Once the act passed in the United States, other nations began to follow suit with their own versions of the Orphan Drug Act. Before governments began passing the acts, the pharma industry could not profit from orphan drugs given the small market size. Government intervention opened a path to profitability for pharmaceutical companies and created an interest to develop orphan drugs.
“Some of the key factors included in study are the growth of orphan drugs market which includes exclusivity options for multiple orphan indications, off-label usage, expansion of orphan indications, and freedom from generic competition,” says market research analyst Shalini Shahani Dewan.
Dewan also told Med Ad News Daily, “Market exclusivity has played a crucial role in the success of the orphan drug market. Currently, as Asian pharmaceutical markets are growing, the opportunities for orphan drugs in Asia are also growing. In next five years, the orphan drugs market will experience steady growth in emerging markets, mostly Asia. The increase is a pro for global orphan drugs market as it is encouraging manufacturers to invest in the research and development of new orphan drugs.”
The BCC Research report analyzes the market for orphan drugs by region, by biological and non-biological drug type, by active ingredient, and by area of medical application. The report reveals why orphan drugs for oncology are the largest category for both biological and non-biological drugs. The report also includes a detailed analysis of all other categories within biological and non-biological drugs.
“For biological orphan drugs, oncology was highest among the nephrology, infectious diseases, and neurology segments,” Dewan told Med Ad News Daily. “For non-biological orphan drugs, oncology was highest among blood disorders, neurology, and fibrosis. There are currently approximately 282 companies plus partners developing 361 orphan drugs in oncology drugs. Oncology represents the biggest disease category for new orphan drugs. Approximately 40 percent of today’s orphans are used to treat cancer.”
BCC Research studied several major pharma in the report, including Amgen, AstraZeneca, Bristol-Myers Squibb Company, Bayer, Baxter, GlaxoSmithKline, Genentech, Sanofi, Roche, Pfizer, Johnson & Johnson, Novartis, Novo Nordisk, and Lundbeck.
Global Market for Orphan Drugs is Expected to Reach $112 Billion in 2017
The total market value for orphan drugs is expected to hit $112 billion in 2017 after increasing at a five-year compound annual growth rate of 5.4 percent, according to a new report from BCC Research, which is a publisher of technology market research reports based in Wellesley, Mass. In 2011, the global market for orphan drugs was valued at $82.6 billion in 2011 and nearly $86 billion in 2012.
Orphan drugs treat orphan diseases, which are the diseases that do not receive significant investment, research, or attention from the medical and pharmaceutical industries. These diseases tend to be rare and are defined by using a ratio of incidence to population in the United States, the European Union, Japan, and other developed countries. In addition, an orphan disease can be a tropical disease whose typical sufferers cannot afford access to pharmaceutical treatment options.
Prior to the passing of the first Orphan Drug Act in 1983 in the United States, orphan diseases did not garner much attention from the pharma industry. Once the act passed in the United States, other nations began to follow suit with their own versions of the Orphan Drug Act. Before governments began passing the acts, the pharma industry could not profit from orphan drugs given the small market size. Government intervention opened a path to profitability for pharmaceutical companies and created an interest to develop orphan drugs.
“Some of the key factors included in study are the growth of orphan drugs market which includes exclusivity options for multiple orphan indications, off-label usage, expansion of orphan indications, and freedom from generic competition,” says market research analyst Shalini Shahani Dewan.
Dewan also told Med Ad News Daily, “Market exclusivity has played a crucial role in the success of the orphan drug market. Currently, as Asian pharmaceutical markets are growing, the opportunities for orphan drugs in Asia are also growing. In next five years, the orphan drugs market will experience steady growth in emerging markets, mostly Asia. The increase is a pro for global orphan drugs market as it is encouraging manufacturers to invest in the research and development of new orphan drugs.”
The BCC Research report analyzes the market for orphan drugs by region, by biological and non-biological drug type, by active ingredient, and by area of medical application. The report reveals why orphan drugs for oncology are the largest category for both biological and non-biological drugs. The report also includes a detailed analysis of all other categories within biological and non-biological drugs.
“For biological orphan drugs, oncology was highest among the nephrology, infectious diseases, and neurology segments,” Dewan told Med Ad News Daily. “For non-biological orphan drugs, oncology was highest among blood disorders, neurology, and fibrosis. There are currently approximately 282 companies plus partners developing 361 orphan drugs in oncology drugs. Oncology represents the biggest disease category for new orphan drugs. Approximately 40 percent of today’s orphans are used to treat cancer.”
BCC Research studied several major pharma in the report, including Amgen, AstraZeneca, Bristol-Myers Squibb Company, Bayer, Baxter, GlaxoSmithKline, Genentech, Sanofi, Roche, Pfizer, Johnson & Johnson, Novartis, Novo Nordisk, and Lundbeck.
Global Market for Orphan Drugs is Expected to Reach $112 Billion in 2017
.png)
No hay comentarios:
Publicar un comentario